EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis and Evaluation Donepezil-Based Dual BuChE/FAAH Inhibitors for Alzheimer’s Disease Therapy

Xiaodan Liu, Yinxin Wu, Yulu Ding, Shilin Hu, Hui Hou, Yicheng Zong, Ziwen Zhang, Wenjian Tang iD

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.6c01848 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Xiaodan Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Anhui Medical University, Hefei230032, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Donepezil, Cholinesterase Inhibitors, Butyrylcholinesterase. Die Arbeit nennt 60 Literaturangaben. Gefördert von: Open Project of Anhui Province Key Laboratory of Occupational Health, Natural Science Foundation of Anhui Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) is multifactorial, prompting multi-target therapy. A series of donepezil-based derivatives were designed, synthesized, and evaluated as dual inhibitors of human butyrylcholinesterase (hBuChE) and fatty acid amide hydrolase (hFAAH). Among them, lead G15 displayed potent and balanced inhibition with IC50 values of 2.44 μM and 0.17 μM, respectively, and favorable selectivity over carboxylesterases CES1/2 (SI 14.4 and 8.4). G15 not only acted as a time-dependent, mixed-type hFAAH inhibitor and a pseudo-irreversible hBuChE inhibitor, but also exhibited good drug-like properties, including high BBB permeability and oral bioavailability (108%). Moreover, G15 chelated Zn2+, protected PC12 cells from oxidative stress, and promoted microglial M1 → M2 polarization. In an Aβ1−42-induced mouse model, G15 significantly reversed cognitive deficits, outperforming donepezil. Therefore, G15 is poised for further development as a promising multi-target candidate for AD therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseDonepezilCholinesterase InhibitorsButyrylcholinesteraseDrug DesignAnimalsHumansRatsMicePC12 CellsStructure-Activity RelationshipMaleAmyloid beta-PeptidesNeuroprotective Agents

Stichwörter der Autor:innen

Alzheimer’s diseasecholinesterase inhibitorsfatty acid amide hydrolasemulti-target directed ligandsneuroprotection

Substanzen

DonepezilCholinesterase InhibitorsButyrylcholinesteraseAmyloid beta-PeptidesNeuroprotective Agents

Autor:innen und Institutionen

  • School of Pharmacy, Anhui Medical University, Hefei230032, China.
  • Kang Chiao School of Xinzhan Zone Hefei City, Hefei230012, China.
  • Jiaxing Maternity and Child Health Care Hospital, Affiliated Women and Children Hospital, Jiaxing University, Jiaxing, Zhejiang314000, China.

ORCID-Profile: Wenjian Tang

Förderung

  • Open Project of Anhui Province Key Laboratory of Occupational Health
  • Natural Science Foundation of Anhui Province

Zitieren

APA

Liu, X., Wu, Y., Ding, Y., Hu, S., Hou, H., Zong, Y., Zhang, Z., & Tang, W. (2026). Design, Synthesis and Evaluation Donepezil-Based Dual BuChE/FAAH Inhibitors for Alzheimer’s Disease Therapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01848

Vancouver

Liu X, Wu Y, Ding Y, Hu S, Hou H, Zong Y, et al. Design, Synthesis and Evaluation Donepezil-Based Dual BuChE/FAAH Inhibitors for Alzheimer’s Disease Therapy. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c01848

BibTeX
@article{Liu2026,
  author = {Liu, Xiaodan and Wu, Yinxin and Ding, Yulu and Hu, Shilin and Hou, Hui and Zong, Yicheng and Zhang, Ziwen and Tang, Wenjian},
  title = {Design, Synthesis and Evaluation Donepezil-Based Dual BuChE/FAAH Inhibitors for Alzheimer’s Disease Therapy},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.6c01848}
}
Kostenlos starten →